Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
CDAK
0.19 as of 3/28/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 11/29/2017 | Series C | $404.14MM | $XXX.XX | $XXX.XX |
| 1/26/2016 | Series B | $296MM | $XXX.XX | $XXX.XX |
| 11/25/2015 | Series A | $76.5MM | $XXX.XX | $XXX.XX |
